It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.
Business Briefs: GSK, Astellas, Vertex and Orexigen
April 22, 2013
4:19 pm
GSK and Astellas kick off the race for a new anemia treatment; Orexigen’s CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.
Business briefs: Reps mum on adverse events; FCC’s new mHealth director; med schools tighten speaking limits
April 11, 2013
6:05 pm
A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation
Business briefs: AstraZeneca, Everyday Health, J&J
April 2, 2013
5:26 pm
AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
CMS releases “Sunshine” final rule: federal preemption, August start date
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
An expert witness in a 2008 lawsuit highlights holes in clinical data, and finds that corporate and published trial data do not necessarily correspond.
Business briefs: Abbott, Sunshine, Allergan and Watson
January 23, 2013
6:45 pm
Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.
Company news: Edelman, CMS, McKesson
November 28, 2012
6:54 pm
Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
BMJ will require authors to disclose clinical trial data
Starting next year, the BMJ will not publish academic papers on drugs or devices unless the relevant anonymized patient-level data are made available for third-party study.
Sunshine Act could scare docs away from commercially-supported CME
Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.